A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Completed
LEO Pharma
Phase 4
2013-01-01
Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective
when used as monotherapy (without other oral medicines or creams) than are newer biologic
injected drugs. However, these oral medications are also less expensive than biologic agents
and may be safer for use in some patients. The purpose of this study is to determine if
adding a topical psoriasis medicine, calcipotriene/betamethasone topical suspension (Taclonex
topical suspension), will improve the severity of psoriasis in patients already on
methotrexate or acitretin and to determine if adding this topical suspension will reduce the
desire of such patients to switch to a biologic agent to treat their psoriasis.
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Completed
University of Pittsburgh
Phase 4
2013-01-01
Oral therapies for psoriasis, including methotrexate and acitretin, are often less effective
when used as monotherapy (without other oral medicines or creams) than are newer biologic
injected drugs. However, these oral medications are also less expensive than biologic agents
and may be safer for use in some patients. The purpose of this study is to determine if
adding a topical psoriasis medicine, calcipotriene/betamethasone topical suspension (Taclonex
topical suspension), will improve the severity of psoriasis in patients already on
methotrexate or acitretin and to determine if adding this topical suspension will reduce the
desire of such patients to switch to a biologic agent to treat their psoriasis.
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
Completed
Tolmar Inc.
Phase 1
2017-04-11
This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation
of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to
the RLD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
